Sepsis in Patients with Ventilator Associated Pneumonia due to Methicillin- Resistant Staphylococcus aureus: Incidence and Impact on Clinical outcomes

Authors

Anupama Raghuram, University of Louisville, Louisville, KYFollow
Martin Gnoni, Our Lady of Bellefonte Hospital, Ashland, KYFollow
Timothy Lee Wiemken, University of LouisvilleFollow
Leslie Beavin, University of LouisvilleFollow
Julio A. Ramirez, University of LouisvilleFollow
Forest W. Arnold, University of LouisvilleFollow
Marcus J. Zervos, Henry Ford Hospital, Detroit, MIFollow
Daniel H. Kett, University of Miami/Jackson Memorial Hospital, Miami, FLFollow
Thomas M. File Jr., Summa Health System, Akron, OHFollow
Gary Stein, Michigan State University, East Lansing, MIFollow
Kimbal D. Ford, Pfizer, Inc., Collegeville, PAFollow
Paula Peyrani, University of LouisvilleFollow
the IMPACT-HAP InvestigatorsFollow

Funder

Funding for this study was provided by Pfizer Inc. The University of Louisville Foundation was responsible for project oversight and distribution of funds to participating institutions.

Abstract

Background: Sepsis is a clinical syndrome associated with organ dysfunction due to a dysregulated host response to infection. Methicillin-resistant Staphylococcus aureus (MRSA) Ventilator-associated pneumonia (VAP) is a serious infection frequently associated with sepsis. The objectives of this study were to define the incidence of sepsis and clinical failure in patients with MRSA VAP.

Methods: This was a secondary analysis of the Improving Medicine through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study database. VAP was defined according to CDC criteria. MRSA VAP was considered when MRSA was isolated from a tracheal aspirate or bronchoalveolar lavage. We used the 3^rd International Consensus Definitions for sepsis. The presence of clinical failure was evaluated at the 14-day follow-up and defined as: 1) progression of baseline signs and symptoms of pneumonia, or 2) death. The Chi- Square Trend Test was utilized to determine the association between the level of organ dysfunction and clinical failure.

Results: MRSA VAP was diagnosed in 205 patients with 138 (67%) presenting with sepsis. Clinical failure occurred in 14% (8/57) of patients without sepsis. Clinical failure occurred in 18% (13/73) of patients with sepsis and 1 organ dysfunction, in 28% (12/43) of patients with sepsis and 2 organ dysfunction, in 28% (5/18) of patients with sepsis and 3 organ dysfunction, and in 100% (4/4) of patients with sepsis and 4 organ dysfunction (p= 0.01).

Conclusions: Sepsis is a frequent complication of MRSA VAP and the number of organ dysfunction correlates with clinical failure in these patients. Effective prevention and treatment of sepsis and associated organ dysfunction is essential to avoid cumulative burden of disease in MRSA VAP.

DOI

10.18297/jri/vol1/iss3/3/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Raghuram, Anupama; Gnoni, Martin; Wiemken, Timothy Lee; Beavin, Leslie; Ramirez, Julio A.; Arnold, Forest W.; Zervos, Marcus J.; Kett, Daniel H.; File, Thomas M. Jr.; Stein, Gary; Ford, Kimbal D.; Peyrani, Paula; and Investigators, the IMPACT-HAP (2017) "Sepsis in Patients with Ventilator Associated Pneumonia due to Methicillin- Resistant Staphylococcus aureus: Incidence and Impact on Clinical outcomes," The University of Louisville Journal of Respiratory Infections: Vol. 1 : Iss. 3 , Article 3.
DOI: https://doi.org/10.18297/jri/vol1/iss3/3/
Available at: https://ir.library.louisville.edu/jri/vol1/iss3/3